BAM

IBS-D vs Bile Acid Malabsorption: The Treatable Condition in 30% of IBS-D Patients

Approximately 25 to 30 percent of patients diagnosed with IBS-D actually have bile acid malabsorption. The symptoms are nearly identical: urgent watery diarrhea, cramping, and bloating. But while IBS-D treatment focuses on dietary changes and symptom management, BAM responds specifically to bile acid sequestrants with 70 to 80 percent response rates. The average time to diagnosis is over 5 years.

Last updated 2026-04-25

Current Consensus

  • Systematic reviews estimate 25 to 30 percent of IBS-D patients have bile acid malabsorption on SeHCAT testing (Wedlake et al., 2009).
  • Bile acid sequestrants produce symptom improvement in 70 to 80 percent of patients with confirmed BAM.
  • SeHCAT is the gold standard diagnostic test but is not available in the United States; serum C4 and therapeutic trials are alternatives.
  • Post-cholecystectomy diarrhea is frequently caused by Type 3 BAM and affects 10 to 20 percent of patients after gallbladder removal.
  • The average diagnostic delay for BAM exceeds 5 years in most healthcare systems.

Open Questions

  • Why primary (Type 2) BAM develops and whether impaired FGF19 signaling is the primary mechanism.
  • When SeHCAT or an equivalent test will become available in the United States.
  • Optimal dosing strategies for bile acid sequestrants across the three BAM types.
  • Long-term effects of bile acid sequestrant therapy beyond 3 years.
  • How often BAM and functional IBS-D coexist as genuinely separate conditions.

Not sure if this applies to you?

Our misdiagnosis quiz evaluates your symptoms against 14 conditions commonly confused with IBS.

Take the Quiz

Medical Disclaimer: The content in this section is for informational and educational purposes only. It does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare professional before making changes to your health regimen. GLP1Gut is a tracking tool, not a medical device.